Abivax (ABVX) Other Accumulated Expenses (2024 - 2026)

Abivax's Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $71.5 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $71.5 million; the TTM figure through Mar 2026 stood at $71.5 million (changed N/A YoY), while the FY2025 annual figure was $71.8 million, up 36.89% from the prior year.
• Other Accumulated Expenses was $71.5 million for Q1 2026 at Abivax, roughly flat from $71.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $71.8 million in Q4 2025 to a low of $52.5 million in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $65.3 million across 3 years, with a median of $71.5 million in 2026.
• Biggest YoY gain for Other Accumulated Expenses was 36.89% in 2025; the steepest drop was 36.89% in 2025.
• A 3-year view of Other Accumulated Expenses shows it stood at $52.5 million in 2024, then surged by 36.89% to $71.8 million in 2025, then slipped by 0.4% to $71.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $71.5 million (Q1 2026), $71.8 million (Q4 2025), and $52.5 million (Q4 2024), per Business Quant data.